Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Clinical neurodiagnostics

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Pashtun Shahim; Magnus Gren; Victor Liman; Ulf Andreasson; Niklas Norgren; Yelverton Tegner; Niklas Mattsson; Niels Andreasen; Martin Öst; Henrik Zetterberg; Bengt Nellgård; Kaj Blennow

Originally published in Scientific reports · 2016-11-07

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Axonal white matter injury is believed to be a major determinant of adverse outcomes following traumatic brain injury (TBI). We hypothesized that measurement of neurofilament light protein (NF-L), a protein found in long white-matter axons, in blood samples, may serve as a suitable biomarker for neuronal damage in TBI patients. To test our hypotheses, we designed a study in two parts: i) we developed an immunoassay based on Single molecule array technology for quantification of NF-L in blood, and ii) in a proof-of-concept study, we tested our newly developed method on serial serum samples from severe TBI (sTBI) patients (n = 72) and controls (n = 35). We also compared the diagnostic and prognostic utility of NF-L with the established blood biomarker S100B. NF-L levels were markedly increased in sTBI patients compared with controls. NF-L at admission yielded an AUC of 0.99 to detect TBI versus controls (AUC 0.96 for S100B), and increased to 1.00 at day 12 (0.65 for S100B). Importantly, initial NF-L levels predicted poor 12-month clinical outcome. In contrast, S100B was not related to outcome.

Discussion

In this study, we developed an ultrasensitive ELISA for quantification of the axonal white matter protein NF-L in serum using the Simoa platform. This assay allows for quantification of NF-L in blood samples down to 2.7 pg/mL, with a limit of detection of 0.27 pg/mL, enabling measurement in all samples, including samples from healthy subjects.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?